Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
22.84
+0.48 (2.15%)
Jan 21, 2025, 4:00 PM EST - Market closed
Pacira BioSciences Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Pacira BioSciences stock have an average target of 27.6, with a low estimate of 8.00 and a high estimate of 57. The average target predicts an increase of 20.84% from the current stock price of 22.84.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for PCRX stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 11 | 11 | 11 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Reiterates $18 | Hold | Reiterates | $18 | -21.19% | Jan 14, 2025 |
| Needham | Needham | Strong Buy Maintains $22 → $30 | Strong Buy | Maintains | $22 → $30 | +31.35% | Jan 13, 2025 |
| Needham | Needham | Strong Buy Maintains $22 → $30 | Strong Buy | Maintains | $22 → $30 | +31.35% | Dec 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $39 | Strong Buy | Reiterates | $39 | +70.75% | Dec 4, 2024 |
| Barclays | Barclays | Hold Maintains $25 → $17 | Hold | Maintains | $25 → $17 | -25.57% | Nov 12, 2024 |
Financial Forecast
Revenue This Year
707.57M
from 674.98M
Increased by 4.83%
Revenue Next Year
722.85M
from 707.57M
Increased by 2.16%
EPS This Year
3.16
from 0.89
Increased by 256.10%
EPS Next Year
3.22
from 3.16
Increased by 1.98%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 732.9M | 806.6M | 912.1M | |||
| Avg | 707.6M | 722.9M | 807.3M | |||
| Low | 670.6M | 542.7M | 639.8M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 8.6% | 14.0% | 26.2% | |||
| Avg | 4.8% | 2.2% | 11.7% | |||
| Low | -0.7% | -23.3% | -11.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 3.60 | 3.89 | 5.22 | |||
| Avg | 3.16 | 3.22 | 3.83 | |||
| Low | 2.79 | 2.54 | 3.07 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 306.4% | 23.1% | 62.1% | |||
| Avg | 256.1% | 2.0% | 19.0% | |||
| Low | 215.1% | -19.6% | -4.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.